Expert Interview
A Second View: Digging into Incyte's Phase 3 TRuE-V data for Ruxolitinib Cream (Opzelura) in treating non-segmental vitiligo
Ticker(s): INCYInstitution: Mount Sinai
- Medical Director for Dermatology at Mount Sinai Healthcare System.
- Manages ~100 patients with hidradenitis supportiva & 50 patients with vitiligo.
- Active in both basic science research and clinical trials, serving as the PI in numerous trials encompassing clinical areas such as psoriasis, atopic dermatitis, Hidradenitis suppurativa, and vitiligo.
Roughly how many patients do you currently manage with non-segmental vitiligo?
Added By: dami_adminHave you prescribed Ruxolitinib? Rough number of patients?
Added By: dami_adminOn a scale from 1-10 (10 being extremely excited) where would you rate your level of excitement for Opzelura as a treatment for vitiligo
Added By: c_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
